Presentation of preliminary results on eblasakimab in a human translational model of chronic obstructive pulmonary disorder at the 7th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases on 2 November. Topline interim data from the FAST-AA study of farudodstat is expected in the first quarter of 2024. A Phase 1 trial of eblasakimab in Japan is expected to be initiated by ASLAN’s partner, Zenyaku Kogyo Co,. in the first half of 2024. ASLAN is conducting continued analyses of the TREK-AD study and plans to submit data on biomarkers and patient reported outcomes for publication at a future scientific congress. An end-of-Phase 2 meeting with the US Food and Drug Administration is expected and subsequent initiation of the Phase 3 clinical program for eblasakimab is expected to occur in 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ASLN:
- ASLAN Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Aslan Pharmaceuticals to co-host KOL on atopic dermatitis treatment
- ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis
- ASLAN Pharmaceuticals Presents New Data From Phase 2b Study of Eblasakimab in Atopic Dermatitis in Late Breaker Presentation at 32nd European Academy of Dermatology and Venereology Congress
- Aslan Pharmaceuticals presents data from Phase 2b study of eblasakimab
